166 related articles for article (PubMed ID: 28787411)
1. First new drug approval for AML in 15 years.
Sheridan C
Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
[No Abstract] [Full Text] [Related]
2. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
3. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
4. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
5. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
6. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
7. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
8. ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Naoe T
Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
[TBL] [Abstract][Full Text] [Related]
9. Availability of FLT3 inhibitors: how do we use them?
Perl AE
Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
[TBL] [Abstract][Full Text] [Related]
10. Gilteritinib Changes AML Landscape.
Saleh N
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469903
[No Abstract] [Full Text] [Related]
11. Midostaurin Gets FDA Nod for AML.
Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
[TBL] [Abstract][Full Text] [Related]
12. A concise review of BCL-2 inhibition in acute myeloid leukemia.
Yogarajah M; Stone RM
Expert Rev Hematol; 2018 Feb; 11(2):145-154. PubMed ID: 29264938
[TBL] [Abstract][Full Text] [Related]
13. Novel Therapeutics in Acute Myeloid Leukemia.
DiNardo CD; Stone RM; Medeiros BC
Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
[TBL] [Abstract][Full Text] [Related]
14. The growing landscape of FLT3 inhibition in AML.
Smith CC
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):539-547. PubMed ID: 31808872
[TBL] [Abstract][Full Text] [Related]
15. Will new agents impact survival in AML?
Rowe JM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
17. Gilteritinib induces differentiation in relapsed and refractory
McMahon CM; Canaani J; Rea B; Sargent RL; Qualtieri JN; Watt CD; Morrissette JJD; Carroll M; Perl AE
Blood Adv; 2019 May; 3(10):1581-1585. PubMed ID: 31122910
[TBL] [Abstract][Full Text] [Related]
18. Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Oncologist; 2021 Feb; 26 Suppl 1(Suppl 1):S10. PubMed ID: 33368797
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.
Levis MJ
Clin Adv Hematol Oncol; 2019 Jun; 17(6):323-325. PubMed ID: 31437132
[No Abstract] [Full Text] [Related]
20. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
